Skip to main content
Premium Trial:

Request an Annual Quote

Benchmarking the Industry: Introducing the Genome Technology Index

Premium

Of the 26 companies that make up the Genome Technology Index, fully half were not public a year ago. At our editorial closing another dozen genome technology IPOs were in the pipeline.

We think an industry this dynamic deserves its own benchmark. So we’ve created one.

What kinds of companies constitute the GTI? In a field characterized by fast-changing technology and ever-adapting strategies, it would be premature to get overly explicit. Especially because many are hedging their bets by pursuing multiple business models.

Suffice it to say, we have three general criteria. First, a GTI company should be chiefly concerned with genomics: what Wall Street types would call a “pure play.” Second, it should be primarily in the business of developing technology ¯ data, software, equipment, consumables, services ¯ as opposed to developing, say, drugs or diagnostics. Finally, a GTI company should be pursuing a broad, commercial market for its technology rather than, for example, working with a small number of exclusive collaborators.

So who’s in the club? Have a look, and let us know what you think: [email protected]

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.